menu
    • menu

    Company profile for Curia

    NEW Drugs in Dev: 5
    Mix GIF-PSE
    News
    Curia Boosts Glasgow Manufacturing And Cell Line Development

    19 Mar 2026

    // PRESS RELEASE

    Curia Releases 2024 Environmental, Social and Governance Report

    28 Oct 2025

    // PRESS RELEASE

    Curia Invests $4 Million To Enhance Sterile API Manufacturing

    27 Oct 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    #1

    Contact Supplier

    Website

    CPhI China

    Booth #E1K37

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.pharmacompass.com/video-supplier-spotlight/curia/small-molecules-generic-apis-and-biologics

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Curia - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Related CompaniesRelated Companies

    About

    Curia is a leading global CDMO with over 30 years of experience supporting clients across drug discovery, development, and commercial manufacturing. Leveraging deep scientific expertise, we deliver integrated solutions spanning small molecules, generic APIs, sterile drug products, and biologics. Our robust global network, advanced technologies, and flexible, scalable teams enable efficient development and reliable supply, accelerating the journey of high-quality therapies from concept to patients worldwide. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CuriaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    26 Corporate Circle, Albany, New York 12203
    Telephone
    Telephone
    +1 5185122000
    Client Email
    Email
    marketing@curiaglobal.com
    Client Website
    Website
    https://curiaglobal.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/curia-cdmo
    youtube
    YouTube
    http://www.youtube.com/@Curiaglobal
    Twitter
    Twitter
    https://x.com/CuriaCDMO
    Contact Info
    Others

    Contact email: customerservice@curiaglobal.com 

     

    Sales Offices: 

    ITALY

    Rozzano - Quinto de’ Stampi

    Via Volturno, 41/43

    20089 - Rozzano (MI) - Italy

    Tel: +39 02 822 72 1

     

    SPAIN

    Parque Tecnológico, Parcela 105

    47151 Boecillo, Valladolid, Spain

    Tel: +34 983 54 80 72

     

    JAPAN

    Level 28 Shinagawa Intercity Tower A

    2-15-1 Konan Minato-ku

    Tokyo 108-6028, Japan

    Tel: +81 3 6717 2807 

     

    CHINA

    Shanggu Commercial Center A-601

    Tian Ta Street, Nankai District

    Tianjin 300381, China

    Tel: +86 22 23412321

     

    INDIA

    713, Exim Link Building

    Opp. Indira Container Yard

    Mulund – Goregoan Link Road, Nahur (W)

    Mumbai – 400078, India

    Tel: 022 67250230-31 

     

    API Manufacturing Sites

     

    UNITED STATES

    RENSSELAER

    33 Riverside Avenue

    Rensselaer, New York 12144 USA

     

    ALBANY

    21 Corporate Circle

    Albany, New York 12203 USA

     

    GRAFTON

    870 Badger Circle

    Grafton, Wisconsin 53024 USA

     

    SPRINGFIELD

    2460 West Bennett Street

    Springfield, Missouri 65807 USA

     

    FRANCE

    BON ENCONTRE

    Zone Industrielle de Laville

    F-47240 - Bon-Encontre - France

     

    TONNEINS

    Avenue du Dr Nicole Bru

    F-47400 - Tonneins - France

     

    GERMANY

    FRANKFURT

    Industriepark Höchst

    65926 - Frankfurt - Germany

     

    ITALY

    ROZZANO - Quinto de’ Stampi

    Via Volturno, 41/43

    20089 - Rozzano (MI) - Italy

    ROZZANO - Valleambrosia

    Via Monterosa, 114

    20089 - Rozzano (MI) - Italy

    ORIGGIO

    Viale Europa, 5

    21040 - Origgio (VA) - Italy

     

    SPAIN

    VALLADOLID

    Parque Tecnológico, Parcela 105

    47151 Boecillo, Valladolid, Spain 

     

    INDIA

    AURANGABAD

    Curia India Pvt. Ltd.

    G-1/1, 1/2, MIDC Area

    Waluj, Aurangabad 431 136

    (Maharashtra), India

     

    AURANGABAD

    Finkem Laboratories Pvt. Ltd.

    G-39/5, MIDC Area

    Waluj, Aurangabad 431 136

    (Maharashtra), India

     

     

     

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI China

    Booth #E1K37

    envelop Contact Supplier

    CPhI China

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/curia-party-content-93457.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Fine Chemicals Catalog

    read-more

      https://www.pharmacompass.com/pdf/party/content/curia-party-content-72093.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

    CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

    PharmaCompass is introducing a new regulatory update that tracks developments in Certificates of Suitability to the Monographs of the European Pharmacopoeia, referred to as CEPs. These certificates are a critical regulatory instrument in the global pharmaceutical supply chain.Also known as a Certification of Suitability (COS), CEPs are issued by the European Directorate for the Quality of Medicines and HealthCare (EDQM), with or without inspection of the manufacturing site. A CEP must be renewed every five years from its original issue date to remain valid, regardless of any revisions made during the interim period. However, a CEP does not replace Good Manufacturing Practice certification.CEPs are recognized as a trusted reference for API quality, thereby simplifying global registration strategies. Apart from Europe, the CEP system is widely used by many regulatory authorities, including those in Canada, Australia, Brazil, Singapore and South Africa. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)CEP 2.0 enhances regulatory clarity, brings efficiency, global interoperability There are several types of CEPs, depending on the nature of the substance and evaluation. The most common type is the Chemical CEP, which confirms that a chemically synthesized API meets standards for purity and impurity control. Then there are Herbal CEPs for herbal substances and preparations.Another key category is the TSE CEP, which addresses risks associated with transmissible spongiform encephalopathies in animal-derived materials. In addition, there are Combined CEPs that may cover multiple aspects, such as chemical quality, TSE risk, and sterility. However, biological products such as vaccines and blood products fall outside the scope of the CEP framework.In 2023, the CEP system underwent a major transformation with the introduction of CEP 2.0, which marks a shift from a largely document-based system to a more structured, transparent, and digitally aligned model. This makes it easier for companies to manage compliance while improving trust among global regulators.While increasing data and compliance requirements for API manufacturers, CEP 2.0 enables better regulatory clarity, streamlined dossier integration, and stronger global acceptance. Overall, CEP 2.0 is designed to enhance regulatory clarity while making the system more efficient and globally interoperable. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Indian firms issued maximum CEPs; Sun Pharma and its subsidiaries, Jubilant Biosys top listIndia topped the charts for CEPs issued, both in terms of new CEPs and revisions in the first quarter (Q1) of 2026. Indian companies were issued 81 new CEPs in Q1 2026 (as against 40 in Q1 2025) and 203 revisions (as against 129 in Q1 2025). In comparison, Chinese companies were issued 42 new CEPs in Q1 2026 (against 25 in Q1 2025) and 53 revisions (against 67 in Q1 2025). Italy came a distant third, followed by Germany and Spain.India’s Sun Pharmaceuticals and its subsidiaries topped the list of companies with the maximum number of CEPs issued— while no new CEP was issued, 27 CEPs were revised in Q1 2026. At second place was Jubilant Biosys — 21 CEPs were revised in Q1 2026.In terms of products, the maximum CEPs were issued for amlodipine besylate (a calcium channel blocker used for treating hypertension), followed by sitagliptin phosphate (a type 2 diabetes medicine) and pregabalin (a drug used to treat neuropathic pain, fibromyalgia, seizures, and generalized anxiety disorder). Both amlodipine besylate and sitagliptin phosphate had not been issued new CEPs or revisions in Q1 2025. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)EDQM introduces new guidelines to accelerate CEP assessments The EDQM charges fees for various services related to CEPs that depend on the type of request or regulatory activity involved. In general, fees apply to handling CEP applications, revisions or renewals and for offering technical advice (where applicants seek scientific or regulatory guidance).In March 2026, the EDQM introduced two new guidelines aimed at accelerating CEP assessments. The first is a reliance-based assessment pathway, which allows regulators to leverage prior approvals from trusted authorities, such as those in the EU, UK, Australia, Canada, and the WHO pre-qualification program. The second is a fast-track assessment route designed to expedite reviews in situations such as medicine shortages and to support initiatives like the EU Critical Medicines Act.Timelines have been significantly compressed under these new pathways. Initial evaluations are completed within 46 working days, compared to up to 115 days under the standard procedure. Applicants are given 30 calendar days to respond to queries, after which regulators complete the final assessment within 23 working days.Another important regulatory update relates to electronic submissions. From April 1, 2026, the EDQM will reject non-compliant CEP applications at the point of submission. All applications must include a validated electronic Common Technical Document (eCTD) dossier along with a proper validation report, submitted in line with the updated Common European Submission Portal (CESP) guidelines. Taken together, these developments signal a more rigorous yet efficient CEP ecosystem. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Our viewThe shift to CEP 2.0 signals a move toward greater transparency, digitalization, and global regulatory alignment. Though enhanced disclosure and stricter e-submission requirements may increase the compliance burden, especially for smaller manufacturers, the long-term gains are expected to be significant. Going forward, companies that invest in data quality and regulatory readiness stand to gain from these changes.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 1166

    https://www.pharmacompass.com/radio-compass-blog/cep-q1-2026-update-cep-2-0-edqm-s-new-guidelines-strengthen-ecosystem-indian-firms-top-list-of-ceps-issued

    #PharmaFlow by PHARMACOMPASS
    09 Apr 2026
    Share Share
    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    The third quarter (Q3) of 2025 witnessed a steady rise in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA). DMFs are used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug productsA total of 323 Type II DMFs were submitted during this period, as opposed to 309 submissions in Q3 2024, marking an increase of 4.53 percent. This is the second highest number since 2018. In Q1 2025, 339 Type II filings were recorded.Across all DMF types (II, III, IV, and V), 479 DMFs were filed in Q3 2025, compared to 394 in Q3 2024, representing a 21.57 percent increase. Out of the 323 Type II DMFs submitted in Q3 2025, 40 had completed their review by the end of Q3, reflecting a processing lag between submission and review completion. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available)China maintains its lead while India posts double-digit growth in DMF submissions China and India continued to dominate DMF submissions in Q3 2025. China retained the top spot with 153 Type II DMFs, matching its submission count from Q3 2024. India recorded 131 DMFs, marking a 20.18 percent increase over 109 filings during the corresponding period last year.The United States stood a distant third with 17 filings, compared to 13 in Q3 2024. Among European nations, Italy recorded eight DMFs, doubling its 2024 tally. The Netherlands filed four, up from three. Spain submitted only one DMF, as against seven submitted in Q3 2024. Taiwan made three filings, up from one submitted in Q3 2024. Together, India, China and Taiwan accounted for about 88.9 percent of all Type II DMFs filed during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) China’s Suzhou Ryway Biotech tops corporate tally; India’s Hetero, Biophore followChina’s Suzhou Ryway Biotech led the company-wise tally with 12 DMF submissions in Q3 2025. The company had not filed any DMFs in Q3 2024.India’s Hetero Group followed with nine DMFs, maintaining the same number of filings as Q3 2024. Biophore India Pharmaceuticals ranked third with six DMFs, doubling its count from three last year.Other notable contributors include Sai Sreyas Pharmaceuticals (India) and Shanghai Haoyuan Chemexpress (China), with five DMFs each. Companies such as SNJ Group, Lunan Pharmaceutical, Allsino Pharmaceutical, Shankus Pharma, Jiangxi Xinganjiang Pharmaceutical, Sunpure Extracts, Lee Pharma, Umedica Laboratories, Linhai Tianyu Pharmaceutical and Maithri Drugs filed four DMFs each. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) Olaparib, semaglutide lead molecular filings; Dr. Reddy’s files DMF for edoxaban & tucatinibDr. Reddy’s Laboratories also featured among key DMF filers in Q3 2025, submitting two DMFs — for edoxaban tosylate monohydrate and tucatinib copovidone. Edoxaban tosylate monohydrate (marketed as Savaysa by Daiichi Sankyo) is a prescription anticoagulant used to reduce the risk of stroke and to treat deep vein thrombosis and pulmonary embolism. Patent exclusivity for Savaysa extends until October 2026 in the United States, with no generic currently available.In terms of molecules, the highest number of DMFs were filed for olaparib, semaglutide, ruxolitinib phosphate, ferric carboxymaltose, and vismodegib, with three DMFs each in Q3 2025.Olaparib, sold by AstraZeneca under the brand name Lynparza, saw DMFs being filed by BDR Lifesciences and Intas Pharmaceuticals from India, and by ScinoPharm Taiwan during the quarter.Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, continued to draw strong interest from API manufacturers. DMFs for semaglutide were filed by three Chinese companies: Yangzhou Aurisco Pharmaceutical, Zhejiang Peptites Biotech, and Fujian Genohope Biotech.Ruxolitinib phosphate, marketed by Incyte as Jakafi, saw three DMFs. Three Indian companies — Alembic Pharmaceuticals, Valary Labs, and Devi Pharmatech — filed DMFs for this API in Q3 2025. Other molecules that received multiple DMF submissions include ferric carboxymaltose (used to treat iron-deficiency anemia) and vismodegib (an oral therapy for basal-cell carcinoma). View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) First-time DMF filings span 17 companies; India leads with nine first-time DMFs The quarter saw first-time DMF filings from 17 companies. India took a lead here with nine first-time DMF filings, followed by China (six), and the US (two).The DMF filings in this quarter included inclisiran sodium (filed by Aurisco Pharmaceutical of China), pacritinib citrate (by TAPI Nl B.V. of the Netherlands), and vosoritide (by Apicore LLC of the US).Out of the 19 first-time DMFs filed in Q3 2025, four completed their Generic Drug User Fee Amendments (GDUFA) review process during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2026: The FDA Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry.Fee rates for fiscal year 2026 were published on July 30, 2025. FDA has revised fees under GDUFA III across all categories. While there is a slight increase in the DMF fee from US$ 95,084 in 2025 to US$ 102,584 in 2026, the ANDA fee has seen a sharp rise: from US$ 321,920 in 2025 to US$ 358,247 in 2026.FY 2025 and FY 2026 User Fee Rates Generic drug fee category Fees rates for FY 2025 Fees rates for FY 2026 Applications:     Abbreviated New Drug Application (ANDA) US$ 3,21,920 US$ 3,58,247 Drug Master File (DMF) US$ 95,084 US$ 1,02,584 Facilities:     Active Pharmaceutical Ingredient (API)—Domestic US$ 41,580 US$ 43,549 API—Foreign US$ 56,580 US$ 58,549 Finished Dosage Form (FDF)—Domestic US$ 2,31,952 US$ 2,38,943 FDF—Foreign US$ 2,46,952 US$ 2,53,943 Contract Manufacturing Organization (CMO)—Domestic US$ 55,668 US$ 57,346 CMO—Foreign US$ 70,668 US$ 72,346 GDUFA Program:     Large size operation generic drug applicant US$ 18,91,664 US$ 19,18,377 Medium size operation generic drug applicant US$ 7,56,666 US$ 7,67,351 Small business generic drug applicant US$ 1,89,166 US$ 1,91,838 Our viewFor several years prior to the pandemic, India had a lead in Type II DMF submissions. In recent years, China has surpassed India in DMF filings. But Q3 2025 numbers indicate that Indian drugmakers are fast catching up. Since DMFs establish trust in APIs from across the world, we feel this healthy competition between drugmakers from the two countries is good for the global pharmaceutical industry. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4085

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-rise-4-5-in-q3-2025-china-holds-lead-india-records-20-growth-in-submissions

    #PharmaFlow by PHARMACOMPASS
    13 Nov 2025
    Share Share
    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 5732

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions

    #PharmaFlow by PHARMACOMPASS
    19 Dec 2024
    Share Share
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024.  Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent.  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each.  The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders).  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available)    GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453   US$ 3,21,920   Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427   US$ 2,31,952 FDF—Foreign US$ 2,35,427   US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629   US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852   US$ 7,56,666 Small business generic drug applicant US$ 1,72,963   US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.   
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 10264

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions

    #PharmaFlow by PHARMACOMPASS
    24 Oct 2024
    Share Share
    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 5324

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities

    #PharmaFlow by PHARMACOMPASS
    08 Aug 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Curia Boosts Glasgow Manufacturing And Cell Line Development
    Curia Boosts Glasgow Manufacturing And Cell Line Development

    19 Mar 2026

    // PRESS RELEASE

    https://curiaglobal.com/about-us/news/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform/

    PRESS RELEASE
    19 Mar 2026
    Share Share
    Curia Releases 2024 Environmental, Social and Governance Report
    Curia Releases 2024 Environmental, Social and Governance Report

    28 Oct 2025

    // PRESS RELEASE

    https://curiaglobal.com/about-us/news/curia-releases-2024-environmental-social-and-governance-esg-report/

    PRESS RELEASE
    28 Oct 2025
    Share Share
    Curia Invests $4 Million To Enhance Sterile API Manufacturing
    Curia Invests $4 Million To Enhance Sterile API Manufacturing

    27 Oct 2025

    // PRESS RELEASE

    https://curiaglobal.com/about-us/news/curia-invests-4-million-to-enhance-sterile-api-manufacturing/

    PRESS RELEASE
    27 Oct 2025
    Share Share
    CDMO Leadership Announcement
    CDMO Leadership Announcement

    01 Apr 2025

    // PRESS RELEASE

    https://curiaglobal.com/about-us/news/cdmo-leadership-announcement/

    PRESS RELEASE
    01 Apr 2025
    Share Share
    Curia Expands Global Sterile Fill-Finish Network
    Curia Expands Global Sterile Fill-Finish Network

    17 Mar 2025

    // PRESS RELEASE

    https://curiaglobal.com/about-us/news/curia-announces-expansions-to-global-network-of-sterile-fill-finish-sites/

    PRESS RELEASE
    17 Mar 2025
    Share Share
    Curia Refinances Senior Secured Credit Facilities
    Curia Refinances Senior Secured Credit Facilities

    10 Mar 2025

    // CONTRACTPHARMA

    https://www.contractpharma.com/breaking-news/curia-refinances-senior-secured-credit-facilities/

    CONTRACTPHARMA
    10 Mar 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Curia Supports Replicate Bioscience's Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

    Details:

    RBI-4000, is a self-replicating (srRNA) rabies vaccine, which is investigated in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.


    Lead Product(s): RBI-4000

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Vaccine

    Recipient: Replicate Bioscience

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 13, 2023

    Company Banner

    01

    Curia

    U.S.A
    arrow
    CPhI China
    Booth #E1K37
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Lead Product(s) : RBI-4000

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Recipient : Replicate Bioscience

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Curia Supports Replicate Bioscience's Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

    Details : RBI-4000, is a self-replicating (srRNA) rabies vaccine, which is investigated in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    September 13, 2023

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humanized anti-SARS-CoV-2 Monoclonal Antibodies from Curia Gl...

    Details:

    Murine monoclonal antibodies have the potential for neutralizing a broader spectrum of SARS-CoV-2 variants and to generate high affinity antibodies that recognize different epitopes on the SARS-CoV-2 spike protein.


    Lead Product(s): Undisclosed

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Antibody, Unconjugated

    Sponsor: Tonix Pharmaceuticals Holding Corp

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement December 12, 2022

    Company Banner

    02

    Curia

    U.S.A
    arrow
    CPhI China
    Booth #E1K37
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Tonix Pharmaceuticals Holding Corp

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humaniz...

    Details : Murine monoclonal antibodies have the potential for neutralizing a broader spectrum of SARS-CoV-2 variants and to generate high affinity antibodies that recognize different epitopes on the SARS-CoV-2 spike protein.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    December 12, 2022

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

    Details:

    IHL-216A (cannabidiol) has been observed to have a greater neuroprotective effect in a rodent model of sports concussion than CBD, and results indicate restoration of the spatial memory deficit post-concussion with IHL-216A administration.


    Lead Product(s): Cannabidiol,Isoflurane

    Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Controlled Substance

    Recipient: Incannex Healthcare

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement August 02, 2022

    Company Banner

    03

    Curia

    U.S.A
    arrow
    CPhI China
    Booth #E1K37
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Lead Product(s) : Cannabidiol,Isoflurane

    Therapeutic Area : Trauma (Emergency, Injury, Surgery)

    Highest Development Status : Preclinical

    Recipient : Incannex Healthcare

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

    Details : IHL-216A (cannabidiol) has been observed to have a greater neuroprotective effect in a rodent model of sports concussion than CBD, and results indicate restoration of the spatial memory deficit post-concussion with IHL-216A administration.

    Product Name : Undisclosed

    Product Type : Controlled Substance

    Upfront Cash : Undisclosed

    August 02, 2022

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    First Patient Dosed in the ENLIGHTEN Biomarker-Guided Global Clinical Trial of DB104 (Liafensine) for Treatment-Resistant Depression

    Details:

    Denovo discovered a novel genetic biomarker for DB104 (liafensine) efficacy using its unique machine learning approach with whole genome sequencing to identify biomarkers that may be predictive of a patient's response to a specific medicine.


    Lead Product(s): Liafensine

    Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Miscellaneous

    Recipient: Denovo Biopharma

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 28, 2022

    Company Banner

    04

    Curia

    U.S.A
    arrow
    CPhI China
    Booth #E1K37
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Lead Product(s) : Liafensine

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase II

    Recipient : Denovo Biopharma

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    First Patient Dosed in the ENLIGHTEN Biomarker-Guided Global Clinical Trial of DB104 (Liafensine) ...

    Details : Denovo discovered a novel genetic biomarker for DB104 (liafensine) efficacy using its unique machine learning approach with whole genome sequencing to identify biomarkers that may be predictive of a patient's response to a specific medicine.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    July 28, 2022

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)

    Details:

    As part of the collaboration, Curia’s experienced process development team will support the GMP production of Replicate Bioscience’s srRNA vectors up to eight-liter scale (8L), which can be used in Phase 1 through pivotal clinical trials.


    Lead Product(s): Undisclosed

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Oligonucleotide

    Sponsor: Replicate Bioscience

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration June 09, 2022

    Company Banner

    05

    Curia

    U.S.A
    arrow
    CPhI China
    Booth #E1K37
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Immunology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Replicate Bioscience

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development ...

    Details : As part of the collaboration, Curia’s experienced process development team will support the GMP production of Replicate Bioscience’s srRNA vectors up to eight-liter scale (8L), which can be used in Phase 1 through pivotal clinical trials.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Undisclosed

    June 09, 2022

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Curia Named Exclusive API Supplier for Recently Approved Acne Treatment

    Details:

    Curia has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.


    Lead Product(s): Clascoterone

    Therapeutic Area: Dermatology Brand Name: Winlevi

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Cassiopea

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement October 30, 2020

    Company Banner

    06

    Curia

    U.S.A
    arrow
    CPhI China
    Booth #E1K37
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Lead Product(s) : Clascoterone

    Therapeutic Area : Dermatology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Cassiopea

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Curia Named Exclusive API Supplier for Recently Approved Acne Treatment

    Details : Curia has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.

    Product Name : Winlevi

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    October 30, 2020

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    BryoLogyx Announces Completion of World’s First GMP Synthesis of Bryostatin-1

    Details:

    Bryostatin-1 is the company’s lead compound being developed to improve patient outcomes by amplifying the response and increasing the durability of targeted cancer immunotherapies.


    Lead Product(s): Bryostatin-1

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Miscellaneous

    Recipient: BryoLogyx Inc

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 13, 2020

    Company Banner

    07

    Curia

    U.S.A
    arrow
    CPhI China
    Booth #E1K37
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Lead Product(s) : Bryostatin-1

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Recipient : BryoLogyx Inc

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    BryoLogyx Announces Completion of World’s First GMP Synthesis of Bryostatin-1

    Details : Bryostatin-1 is the company’s lead compound being developed to improve patient outcomes by amplifying the response and increasing the durability of targeted cancer immunotherapies.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    October 13, 2020

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Curia Selected to Support AstraZeneca in Delivery of COVID-19 Vaccine

    Details:

    Curia has been chosen to contribute to the supply of the vaccine candidate through sterile fill/finish of AZD1222 at Curia’s drug product manufacturing facility in Albuquerque, New Mexico.


    Lead Product(s): ChAdOx1 nCoV-19

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Vaccine

    Sponsor: AstraZeneca

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement September 03, 2020

    Company Banner

    08

    Curia

    U.S.A
    arrow
    CPhI China
    Booth #E1K37
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Lead Product(s) : ChAdOx1 nCoV-19

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : AstraZeneca

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Curia Selected to Support AstraZeneca in Delivery of COVID-19 Vaccine

    Details : Curia has been chosen to contribute to the supply of the vaccine candidate through sterile fill/finish of AZD1222 at Curia’s drug product manufacturing facility in Albuquerque, New Mexico.

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    September 03, 2020

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Tryp Therapeutics Partners with Curia to Manufacture a Proprietary Psilocybin-based Drug

    Details:

    Curia will provide research, development and cGMP manufacturing of a proprietary psilocybin active pharmaceutical ingredient to support the clinical development of Psilocybin (TRP-8802), TRP-8803 and TRP-8804 programs.


    Lead Product(s): Psilocybine

    Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

    Study Phase: UndisclosedProduct Type: Controlled Substance

    Sponsor: Tryp Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership August 13, 2020

    Company Banner

    09

    Curia

    U.S.A
    arrow
    CPhI China
    Booth #E1K37
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Lead Product(s) : Psilocybine

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Undisclosed

    Partner/Sponsor/Collaborator : Tryp Therapeutics

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Tryp Therapeutics Partners with Curia to Manufacture a Proprietary Psilocybin-based Drug

    Details : Curia will provide research, development and cGMP manufacturing of a proprietary psilocybin active pharmaceutical ingredient to support the clinical development of Psilocybin (TRP-8802), TRP-8803 and TRP-8804 programs.

    Product Name : Undisclosed

    Product Type : Controlled Substance

    Upfront Cash : Undisclosed

    August 13, 2020

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    ViralClear, Curia Enter COVID-19 Partnership

    Details:

    The companies together are undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19, either as a stand-alone treatment or in combination with other antiviral agents or immune modulators.


    Lead Product(s): Merimepodib,Remdesivir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Vicromax

    Study Phase: Phase IIProduct Type: Miscellaneous

    Sponsor: BioSig Technologies

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership July 08, 2020

    Company Banner

    10

    Curia

    U.S.A
    arrow
    CPhI China
    Booth #E1K37
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCuria - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.

    Lead Product(s) : Merimepodib,Remdesivir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : BioSig Technologies

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    ViralClear, Curia Enter COVID-19 Partnership

    Details : The companies together are undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19, either as a stand-alone treatment or in combination with other antiviral agents or immune modulators.

    Product Name : Vicromax

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    July 08, 2020

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    Drug Product Manufacturing

    Discover their expertise for : Drug Product Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    Inspections and registrations

    Check the inspections & registration from this company

    Others

    read-more
    read-more

    ABOUT THIS PAGE

    Contact Curia and get a quotation

    Curia is a supplier offers 132 products (APIs, Excipients or Intermediates).

    Find a price of Betamethasone Dipropionate bulk with DMF, CEP, JDMF offered by Curia

    Find a price of Betamethasone Sodium Phosphate bulk with DMF, CEP, JDMF offered by Curia

    Find a price of Clobetasol Propionate bulk with DMF, CEP, JDMF offered by Curia

    Find a price of Cyclosporine bulk with DMF, CEP, JDMF offered by Curia

    Find a price of Dorzolamide Hydrochloride bulk with DMF, CEP, JDMF offered by Curia

    Find a price of Furosemide bulk with DMF, CEP, WC offered by Curia

    Find a price of Hydrocortisone bulk with DMF, CEP, JDMF offered by Curia

    Find a price of Minocycline Hydrochloride bulk with DMF, CEP, JDMF offered by Curia

    Find a price of Alclometasone Dipropionate bulk with DMF, JDMF offered by Curia

    Find a price of Betamethasone Valerate bulk with CEP, JDMF offered by Curia

    Find a price of Bromocriptine Mesylate bulk with DMF, CEP offered by Curia

    Find a price of Budesonide bulk with DMF, CEP offered by Curia

    Find a price of Chlorthalidone bulk with DMF, CEP offered by Curia

    Find a price of Dexamethasone bulk with CEP, JDMF offered by Curia

    Find a price of Dexamethasone Sodium Phosphate bulk with DMF, CEP offered by Curia

    Find a price of Dihydroergotamine Mesylate bulk with DMF, CEP offered by Curia

    Find a price of Etonogestrel bulk with DMF, CEP offered by Curia

    Find a price of Exemestane bulk with DMF, CEP offered by Curia

    Find a price of Fluorometholone bulk with DMF, JDMF offered by Curia

    Find a price of Flutamide bulk with DMF, CEP offered by Curia

    Find a price of Fluticasone Propionate bulk with DMF, CEP offered by Curia

    Find a price of Hydrocortisone Butyrate bulk with DMF, JDMF offered by Curia

    Find a price of Medroxyprogesterone Acetate bulk with DMF, CEP offered by Curia

    Find a price of Mifepristone bulk with DMF, JDMF offered by Curia

    Find a price of Mometasone Furoate bulk with DMF, CEP offered by Curia

    Find a price of Olopatadine Hydrochloride bulk with DMF, JDMF offered by Curia

    Find a price of Pancuronium Bromide bulk with DMF, CEP offered by Curia

    Find a price of Prednisolone Sodium Phosphate bulk with DMF, JDMF offered by Curia

    Find a price of Rocuronium Bromide bulk with DMF, CEP offered by Curia

    Find a price of Testosterone bulk with DMF, CEP offered by Curia

    Find a price of Triamcinolone Acetonide bulk with DMF, JDMF offered by Curia

    Find a price of Vecuronium Bromide bulk with DMF, JDMF offered by Curia

    Find a price of Alclometasone Dipropionate bulk with JDMF offered by Curia

    Find a price of Altrenogest bulk with DMF offered by Curia

    Find a price of Amphetamine Aspartate bulk with DMF offered by Curia

    Find a price of Amphetamine Sulfate bulk with DMF offered by Curia

    Find a price of Argatroban bulk with DMF offered by Curia

    Find a price of Argatroban Monohydrate bulk with DMF offered by Curia

    Find a price of Azelastine Hydrochloride bulk with DMF offered by Curia

    Find a price of Aztreonam bulk with DMF offered by Curia

    Find a price of Beclomethasone Dipropionate bulk with CEP offered by Curia

    Find a price of Betamethasone bulk with JDMF offered by Curia

    Find a price of Betamethasone Sodium Phosphate bulk with CEP offered by Curia

    Find a price of Cyclofenil bulk with JDMF offered by Curia

    Find a price of Cyclosporine bulk with DMF offered by Curia

    Find a price of Cyproterone Acetate bulk with CEP offered by Curia

    Find a price of Deoxycholic Acid bulk with DMF offered by Curia

    Find a price of Deucravacitinib bulk with DMF offered by Curia

    Find a price of Dexamethasone bulk with JDMF offered by Curia

    Find a price of Dexmethylphenidate bulk with DMF offered by Curia

    Find a price of Dextroamphetamine Saccharate bulk with DMF offered by Curia

    Find a price of Diatrizoate Meglumine bulk with DMF offered by Curia

    Find a price of Diatrizoate Sodium bulk with DMF offered by Curia

    Find a price of Dihydroergocristine bulk with CEP offered by Curia

    Find a price of Ergotamine Tartrate bulk with DMF offered by Curia

    Find a price of Finasteride bulk with CEP offered by Curia

    Find a price of Fludrocortisone Acetate bulk with DMF offered by Curia

    Find a price of Hexetidine bulk with CEP offered by Curia

    Find a price of Hydrocortisone bulk with DMF offered by Curia

    Find a price of Hydrocortisone Acetate bulk with CEP offered by Curia

    Find a price of Hydrocortisone Sodium Succinate bulk with CEP offered by Curia

    Find a price of Levocabastine bulk with CEP offered by Curia

    Find a price of Loteprednol Etabonate bulk with DMF offered by Curia

    Find a price of Mafenide bulk with DMF offered by Curia

    Find a price of Methylphenidate Hydrochloride bulk with DMF offered by Curia

    Find a price of Methylprednisolone Acetate bulk with DMF offered by Curia

    Find a price of Methylprednisolone Hemisuccinate bulk with DMF offered by Curia

    Find a price of Milrinone bulk with JDMF offered by Curia

    Find a price of Minocycline Hydrochloride bulk with DMF offered by Curia

    Find a price of Naltrexone Methobromide bulk with DMF offered by Curia

    Find a price of Niflumic Acid bulk with CEP offered by Curia

    Find a price of Olopatadine Hydrochloride bulk with DMF offered by Curia

    Find a price of Pralidoxime Chloride bulk with DMF offered by Curia

    Find a price of Pramipexole Dihydrochloride bulk with DMF offered by Curia

    Find a price of Prednisone bulk with DMF offered by Curia

    Find a price of Regadenoson Monohydrate bulk with DMF offered by Curia

    Find a price of Sodium Oxybate bulk with DMF offered by Curia

    Find a price of Tapentadol bulk with DMF offered by Curia

    Find a price of Testosterone Cypionate bulk with DMF offered by Curia

    Find a price of Triamcinolone Acetonide bulk with JDMF offered by Curia

    Find a price of Trientine Hydrochloride bulk with DMF offered by Curia

    Find a price of Upadacitinib bulk with DMF offered by Curia

    Find a price of Argatroban bulk offered by Curia

    Find a price of Bamifylline bulk offered by Curia

    Find a price of Betamethasone Acetate bulk offered by Curia

    Find a price of Betamethasone Benzoate bulk offered by Curia

    Find a price of Brexanolone bulk offered by Curia

    Find a price of Camizestrant bulk offered by Curia

    Find a price of Cantharidin bulk offered by Curia

    Find a price of Chlorthalidone bulk offered by Curia

    Find a price of Cifenline bulk offered by Curia

    Find a price of Clobetasol Propionate bulk offered by Curia

    Find a price of Cyclosporine bulk offered by Curia

    Find a price of Deflazacort bulk offered by Curia

    Find a price of Dexamethasone Palmitate bulk offered by Curia

    Find a price of Dexmethylphenidate bulk offered by Curia

    Find a price of Diethylamine Salicylate bulk offered by Curia

    Find a price of Dihydroergotamine Mesylate bulk offered by Curia

    Find a price of Donepezil bulk offered by Curia

    Find a price of Dorzolamide Hydrochloride bulk offered by Curia

    Find a price of Epinephrine bulk offered by Curia

    Find a price of Etrasimod bulk offered by Curia

    Find a price of Etrasimod Arginine bulk offered by Curia

    Find a price of Fluorometholone Acetate bulk offered by Curia

    Find a price of Flurogestone Acetate bulk offered by Curia

    Find a price of Flutamide bulk offered by Curia

    Find a price of Ganaxolone bulk offered by Curia

    Find a price of Hydrocortisone Valerate bulk offered by Curia

    Find a price of Medroxyprogesterone Acetate bulk offered by Curia

    Find a price of Melengestrol Acetate bulk offered by Curia

    Find a price of Methylprednisolone bulk offered by Curia

    Find a price of Methylprednisolone Aceponate bulk offered by Curia

    Find a price of Methylprednisolone Acetate bulk offered by Curia

    Find a price of Methylprednisolone Sodium Succinate bulk offered by Curia

    Find a price of Paliperidone Palmitate bulk offered by Curia

    Find a price of Pancuronium Bromide bulk offered by Curia

    Find a price of Pethidine Hydrochloride bulk offered by Curia

    Find a price of Prednicarbate bulk offered by Curia

    Find a price of Prednisolone bulk offered by Curia

    Find a price of Propacetamol HCl bulk offered by Curia

    Find a price of Relacorilant bulk offered by Curia

    Find a price of Remibrutinib bulk offered by Curia

    Find a price of Rocuronium Bromide bulk offered by Curia

    Find a price of Samidorphan bulk offered by Curia

    Find a price of Sirolimus bulk offered by Curia

    Find a price of Sodium Oxybate bulk offered by Curia

    Find a price of Tamsulosin bulk offered by Curia

    Find a price of Testosterone Enanthate bulk offered by Curia

    Find a price of Testosterone Propionate bulk offered by Curia

    Find a price of Testosterone Undecanoate bulk offered by Curia

    Find a price of Tyloxapol API bulk offered by Curia

    Find a price of Vamorolone bulk offered by Curia

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search